Research Article

Relationship between Neutrophil Gelatinase-Associated Lipocalin, Eosinophil Cationic Protein, Cytokines, and Atopic Sensitization in Patients with Allergic Diseases

Jong Weon Choi,1 Moon Hee Lee,2 and Tatsuyoshi Fujii3

1Department of Laboratory Medicine, College of Medicine, Inha University, Incheon, Republic of Korea
2Department of Internal Medicine, College of Medicine, Inha University, Incheon, Republic of Korea
3Department of Internal Medicine, Tsukuba University Hospital Mito Clinical Education and Training Center, Mito Kyodo General Hospital, Ibaraki, Japan

Correspondence should be addressed to Jong Weon Choi; jwchoi@inha.ac.kr

Received 3 March 2022; Revised 9 May 2022; Accepted 23 May 2022; Published 6 June 2022

Academic Editor: Mateusz Maciejczyk

Copyright © 2022 Jong Weon Choi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The effect of neutrophil gelatinase-associated lipocalin (NGAL) on eosinophil activation, atopic sensitization, and systemic inflammation in allergic diseases has rarely been investigated. This study aimed to investigate the relationship between NGAL, eosinophil cationic protein (ECP), cytokines, and allergen-specific immunoglobulin E (sIgE) in allergic diseases. A total of 136 patients with allergies and 58 healthy individuals were evaluated. The concentrations of NGAL, ECP, tumor necrosis factor-α (TNF-α), interleukin-5 (IL-5), sIgE, total IgE (tIgE), and high-sensitivity C-reactive protein (hsCRP) were measured. The transforming growth factor-β1 (TGF-β1) level was measured as a profibrotic marker of bronchial asthma. Allergic patients had significantly higher NGAL, ECP, and hsCRP levels than healthy individuals. However, there was no significant difference in NGAL levels between patients with positive and negative ECP tests and those with high and low sIgE scores. Asthmatic patients with elevated NGAL exhibited a significantly higher TGF-β1 level than those without elevated NGAL. However, no significant difference was observed in the ECP, IL-5, and sIgE levels between the two groups. Among the patients with a positive ECP test, subjects with elevated hsCRP had two times higher NGAL levels than those without elevated hsCRP. NGAL was positively correlated with TNF-α, TGF-β1, and hsCRP, but not with ECP, IL-5, tIgE, and sIgE. An elevated NGAL level led to a 1.3-fold increase in the prevalence of high TGF-β1 (odds ratio: 1.31; 95% CI: 1.04–2.58; P < 0.001). In conclusion, NGAL elevation may be more closely linked to allergic inflammation and a possible fibrotic change in the airways than to the severity of eosinophil activation and atopic sensitization.

1. Introduction

Allergic diseases are a group of immune-mediated illnesses characterized by a hyper-responsiveness of the immune system to environmental antigens [1]. They are primarily caused by the interaction of an allergen with its specific immunoglobulin E (sIgE) on the surface of mast cells, which leads to the secretion of chemical mediators that induce the production of inflammatory cells [2]. According to the type of allergy and the target organ of contact with allergens, various clinical manifestations can occur in the airways, skin, or gastrointestinal tract, such as bronchial asthma, urticaria, eczema, vomiting, and diarrhea [3].

Eosinophil cationic protein (ECP) is a cytotoxic protein present in the protein matrix of eosinophils [4]. ECP is released from the secondary granules of activated eosinophils and is largely responsible for damaging the bronchial mucosa [5]. ECP is closely related to allergic diseases and contributes to airway inflammation observed in these diseases. During the progression of allergic diseases, ECP, released locally from the inflamed mucosa, infuses into the circulating blood, resulting in systemic inflammation [6].
Neutrophil gelatinase-associated lipocalin (NGAL), also called lipocalin-2, is a 25kDa glycoprotein associated with neutrophilic inflammation. NGAL is known as an acute phase protein because its blood level is increased under various inflamed conditions [7]. NGAL was initially identified as a matrix protein of specific granules of human neutrophils but later found to be secreted by different cells, including renal tubular cells, immune cells, and respiratory epithelial cells [8]. As extracellular matrix proteins play an important role in the process of airway remodeling, NGAL has been regarded as a potential indicator of airway structural alteration in patients with pulmonary diseases [9]. However, there have been conflicting results on NGAL in patients with allergies. In some studies, NGAL was significantly elevated in patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) [10, 11]. However, in another study, there was no significant difference in NGAL levels between asthmatic patients and healthy individuals [12].

Previous studies of NGAL have mainly focused on the clinical use of NGAL as an indicator of acute kidney injury [13] or as a predictor for the progression of chronic kidney disease [14]. There are few studies on NGAL production and its relationship with ECP, sIgE, cytokines, and inflammatory parameters in allergic diseases [10–12]. Therefore, this study investigated whether plasma NGAL is elevated in allergic diseases in proportion to the severity of eosinophil activation and atopic sensitization. This study also evaluated the association between NGAL and fibrotic changes in the airways by measuring the level of transforming growth factor-β1 (TGF-β1), which is a promising profibrotic biomarker of airway remodeling in bronchial asthma.

2. Materials and Methods

2.1. Subjects. This cross-sectional study was conducted in 136 patients (71 men and 65 women) who were diagnosed with allergic diseases. Age- and sex-matched healthy individuals (n = 58) without any evidence of allergy and inflammation were enrolled as the control group. The patients’ age ranged from 20 to 72 years (mean age: 50.2 years). Subjects with confirmed allergy were chosen based on the following criteria: a clinical history of allergic reaction, elevated serum total IgE (tIgE) level, and positive sIgE tests for inhalant and/or food allergens according to the ImmunoCAP assay. The patients had the following diseases: bronchial asthma (n = 83), food allergy (n = 31), allergic rhinitis (n = 12), atopic dermatitis (n = 5), allergic conjunctivitis (n = 3), and anaphylaxis (n = 2). The mean duration of allergies was 1.4 years, and 75 (55.1%) patients had a history of allergic attack (Table 1). Several parameters, including NGAL, ECP, interleukin-5 (IL-5), tumor necrosis factor-α (TNF-α), TGF-β1, sIgE, tIgE, and high-sensitivity C-reactive protein (hsCRP) levels, were measured. The following subjects were excluded from the study to avoid the effects of their diseases on ECP and NGAL levels: (a) those with medication history, including corticosteroids or histamine antagonists; (b) those with acute infection with fever, chronic illness, and recent surgery; and (c) those with renal dysfunction, cardiovascular diseases, and sepsis. Subjects with missing values in medical

![Table 1: Clinical presentation of patients with allergic diseases.](image-url)

| Parameters                  | Patients with allergic diseases (n = 136) |
|-----------------------------|-----------------------------------------|
| Age (years)                 | 50.2 ± 12.9                             |
| Sex (men/women)             | 71/65                                   |
| Allergy history             |                                         |
| Duration of allergic diseases (years) | 1.4 (0.5–3.5)           |
| Patients with allergic attacks (n, %) | 75 (55.1)                          |
| Frequency of attack/year    | 1.9 (0–6)                               |
| Allergy type (n, %)         |                                         |
| Inhalant allergy            | 105 (77.2)                              |
| Food allergy                | 31 (22.8)                               |
| Clinical parameters (n, %)  |                                         |
| Current smoking             | 28 (20.6)                               |
| Overweight (BMI ≥ 25.0 kg/m²) | 43 (31.6)                              |
| Hypertension                | 25 (18.4)                               |

Data are expressed as mean ± SD, median (range), or frequency (percentage). BMI: body mass index.
(cow’s milk and egg white) was performed using a fluoroenzyme immunoassay (ImmunoCAP 100, Phadia AB, Uppsala, Sweden). An sIgE level ≥0.35 kU/L, namely, ≥class 1, was defined as allergic sensitization [17]. The sIgE score was obtained by the summation of the class, which was given to each patient according to the grade of allergic sensitization. High and low scores of sIgE were determined as >3 and ≤3, respectively, based on the median sIgE level of the allergic patients. The concentration of tIgE was measured using an immunoradiometric assay (Coat-A-Count Total IgE IRMA, Siemens Healthcare Diagnostics, Tarrytown, NY, USA). An sIgE level ≥0.35 kU/L, namely, ≥class 1, was defined as allergic sensitization [17]. The sIgE score was obtained by the summation of the class, which was given to each patient according to the grade of allergic sensitization. High and low scores of sIgE were determined as >3 and ≤3, respectively, based on the median sIgE level of the allergic patients. The concentration of tIgE was measured using an immunoradiometric assay (Coat-A-Count Total IgE IRMA, Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The concentrations of IL-5, TNF-α, and TGF-β1 were measured using enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN, USA; BD Inc., San Diego, CA, USA; and RayBiotech, Norcross, GA, USA, respectively) according to the manufacturer’s instructions. As a profibrotic marker of the airways, TGF-β1 was measured only in patients with bronchial asthma. The hsCRP level was measured using a particle-enhanced immunonephelometric assay with a chemical analyzer (Hitachi 7600; Hitachi, Tokyo, Japan). An elevation of hsCRP level was defined as >0.5 mg/dL, which was based on the cutoff value (95% confidence interval) for hsCRP levels in healthy individuals. Blood eosinophil counts were estimated using an automated analyzer (ADVIA 120; Siemens, Forchheim, Germany).

2.3. Statistical Analysis. Data were expressed as mean ± standard deviation (SD) or median (interquartile range: IQR). Categorical variables were presented as frequency and percentage. The normality of data was tested by the Kolmogorov-Smirnov test. Continuous variables with normal distribution were analyzed by Student t test. Nonnormally distributed data were analyzed by the Mann–Whitney U test. The chi-square test was used to analyze categorical variables. The relationship between NGAL, ECP, cytokines, and allergy-related parameters was assessed by multivariate linear regression analysis with adjustment for potential confounders, such as age, sex, body mass index (BMI), systolic blood pressure (SBP), and current smoking. The association between elevated NGAL and the prevalence of high TGF-β1 was evaluated by multivariate logistic regression analysis. Statistical analysis was performed with the SPSS software package (version 26; IBM SPSS Statistics, Armonk, NY, USA) and the MedCalc software package (version 20; MedCalc Software Ltd., Ostend, Belgium). Values of P < 0.05 were considered statistically significant.

3. Results

3.1. Characteristics of Subjects. ECP, tIgE, sIgE, and the ECP/Eo ratio were significantly higher in allergic patients than in healthy individuals. Of the 136 patients, 56 (41.2%) patients had elevated NGAL levels, and 91 (66.9%) patients had elevated hsCRP levels (Table 2). The NGAL level of the allergic patients was 137.5 ng/mL, significantly higher than that (69.5 ng/mL) of the control subjects (P < 0.001) (Figure 1).

3.2. NGAL in Allergic Patients with and without Systemic Inflammation. The NGAL level of allergic patients with systemic inflammation was significantly higher than that of allergic patients without systemic inflammation (152.3 ng/mL vs 86.7 ng/mL, P < 0.001). However, there was no significant difference in the NGAL levels between allergic patients without systemic inflammation and healthy individuals. Patients with systemic inflammation exhibited higher ECP/Eo ratios than those without systemic inflammation; however, no significant difference in ECP, tIgE, and sIgE levels was observed between the two groups (Table 3).

3.3. ECP and Cytokines in Patients with Elevated NGAL. Patients with elevated NGAL had significantly higher TNF-α, TGF-β1, and hsCRP levels than those without elevated NGAL (71.5 pg/mL, 3.52 ng/mL, and 2.13 mg/dL vs 30.8 pg/mL, 1.87 ng/mL, and 0.45 mg/dL, respectively, P < 0.001). However, there was no significant difference in ECP, IL-5, the ECP/Eo ratio, and sIgE levels between the groups (Table 4).

3.4. NGAL and Cytokines according to ECP and the ECP/Eo Ratio. Compared to patients with a negative ECP test, those with a positive ECP test had significantly higher IL-5, tIgE, and sIgE levels. Similarly, patients with elevated ECP/Eo ratios had higher levels of the corresponding parameters than those without elevated ECP/Eo ratios (P < 0.001). However, no significant differences in NGAL and TGF-β1 levels were observed between patients with positive and negative ECP tests or between patients with and without elevated ECP/Eo ratios (Table 5).

3.5. ECP and NGAL according to sIgE and hsCRP Levels. ECP and the ECP/Eo ratio were significantly higher in patients with a high sIgE score than in those with a low sIgE score. However, no significant difference was observed in NGAL and proinflammatory cytokine levels between the two groups. The plasma NGAL level was two-fold higher in patients with a positive ECP test and elevated hsCRP than in those with a positive ECP test and nonelevated hsCRP (181.5 ng/mL vs 90.2 ng/mL, P < 0.001) (Table 6).

3.6. Relationship between NGAL, ECP, and Allergy-Related Parameters. After adjusting for potential confounders, NGAL was positively correlated with TNF-α (r = 0.332), TGF-β1 (r = 0.285), and hsCRP (r = 0.413), but not with ECP, IL-5, and tIgE (Table 7). Scatter plots of the relationship between NGAL and TGF-β1 in patients with bronchial asthma and the relationship between ECP and IL-5 in allergic patients are shown in Figure 2. NGAL and ECP were positively correlated with TGF-β1 (r = 0.009x + 1.436, r² = 0.127, P < 0.001) and IL-5 (y = 0.029x + 13.761, r² = 0.102, P < 0.001), respectively (Figure 2).

3.7. Odds Ratio for High TGF-β1 with NGAL Elevation. To determine whether NGAL elevation is associated with the prevalence of high TGF-β1, multivariate logistic regression analysis was performed. An elevated NGAL level (>150 ng/mL) resulted in a 1.3 times increase in the prevalence of high TGF-β1 with adjustment for confounders (odds ratio: 1.31, 95% CI: 1.04–2.58, P < 0.001) (Table 8).
4. Discussion

In the present study, the relationship between NGAL, ECP, cytokines, sIgE, tIgE, and hsCRP was investigated in patients with allergic diseases. The major findings of this study were as follows: (1) NGAL production was enhanced in allergies; however, increased NGAL production was not associated with a positive ECP test and a high sIgE score; (2) allergic patients without systemic inflammation did not differ from healthy individuals in terms of NGAL; and (3) NGAL was closely associated with TGF-β1 and TNF-α, but not with ECP and sIgE. These findings are in accordance with the
results of a previous study, which demonstrated that NGAL was a prognostic biomarker in asthma-COPD overlap syndrome characterized by airway inflammation [18].

Atopic sensitization refers to a condition with an increased sIgE level after exposure to allergens. It is usually defined as an increase in the concentration to ≥0.35 kU/L of sIgE in response to the corresponding allergens [17]. The sIgE is fundamental to the pathogenesis of allergic disorders, with the relationship between the serum IgE level and the severity of allergic diseases reported widely. In one study, serum IgE levels were significantly higher in asthmatic patients with decreased lung function than in those without decreased lung function [19]. Wood et al. [20] demonstrated that sIgE levels were significantly correlated with both pulmonary function and asthmatic symptoms in patients with inhalant allergies. The present study evaluated whether the plasma NGAL level is more elevated in patients with severe sensitization than in those with mild sensitization. In our study, no significant difference was noted in NGAL concentrations between patients with high and low sIgE scores. These results suggest that the severity of atopic sensitization has no meaningful effect on NGAL elevation in patients with allergic diseases.

ECP can induce epithelial cell death via necrosis and apoptosis pathways [21, 22]. The administration of recombinant ECP triggers smooth muscle cell death within 1 h [23]. The blood ECP level represents the extent of eosinophil activation. Recently, several studies reported that the ECP/Eo ratio was more closely correlated with the clinical symptoms of asthmatic patients than ECP and eosinophil parameters.

Table 3: NGAL levels in allergic patients with and without systemic inflammation.

| Parameters | Allergic patients (n = 136) | Healthy subjects (n = 58) |
|------------|----------------------------|--------------------------|
|            | With systemic inflammation (n = 91) | Without systemic inflammation (n = 45) |
| Clinical parameters | | |
| Age (years) | 50.8 ± 12.2 | 49.7 ± 13.6 | 51.6 ± 12.5 |
| Sex (male, %) | 47 (53.2) | 24 (53.3) | 31 (53.4) |
| Laboratory parameters | | |
| NGAL (ng/mL) | 152.3 (118.5–214.0) | 86.7 (59.5–132.0) | 69.5 (50.7–110.5) |
| ECP (μg/L) | 47.6 (36.1–90.2) | 41.2 (31.0–86.5) | 11.7 (3.5–16.4) |
| ECP/Eo ratio | 0.29 (0.08–6.57) | 0.20 (0.04–5.02) | 0.08 (0.03–0.42) |
| hsCRP (mg/dL) | 2.16 (0.61–4.07) | 0.23 (0.12–0.43) | 0.09 (0.06–0.38) |
| tIgE (IU/mL) | 365.1 (27.5–891.4) | 320.7 (23.1–854.6) | 13.8 (4.5–92.1) |
| sIgE score | 3 (2–5) | 3 (2–5) | 0 (0–0) |

Data are expressed as mean ± SD, median (IQR), or frequency (percentage). *Significant (P < 0.05), compared with allergic patients without systemic inflammation. †Significant (P < 0.05), compared with healthy subjects. NGAL: neutrophil gelatinase-associated lipocalin; ECP: eosinophil cationic protein; ECP/Eo ratio: ECP/eosinophil count ratio; hsCRP: high-sensitivity C-reactive protein; tIgE: total immunoglobulin E; and sIgE: specific IgE.

Table 4: ECP and inflammatory parameters according to the NGAL level in allergic patients.

| Parameters | Elevated NGAL (n = 56) | Nonelevated NGAL (n = 80) | P value |
|------------|-------------------------|--------------------------|---------|
| Clinical parameters | | | |
| Age (years) | 51.4 ± 13.1 | 50.6 ± 12.2 | 0.715 |
| Sex (male, %) | 29 (51.7) | 38 (47.5) | 0.631 |
| Allergic parameters | | | |
| ECP (μg/L) | 58.2 (29.7–96.4) | 37.6 (25.8–83.5) | 0.172 |
| ECP/Eo ratio | 0.31 (0.10–6.53) | 0.23 (0.08–5.13) | 0.253 |
| tIgE (IU/mL) | 381.5 (31.5–893.6) | 310.6 (24.3–681.6) | 0.214 |
| sIgE score | 4 (2–5) | 3 (2–5) | 0.307 |
| Inflammatory parameters | | | |
| TNF-α (pg/mL) | 71.5 (7.3–290.4) | 30.8 (6.5–214.6) | <0.001 |
| IL-5 (pg/mL) | 14.9 (8.5–28.6) | 11.2 (6.4–22.9) | 0.568 |
| TGF-β1 (ng/mL)* | 3.52 (1.65–4.58) | 1.87 (1.03–3.54) | <0.001 |
| hsCRP (mg/dL) | 2.13 (0.42–3.27) | 0.45 (0.02–1.62) | <0.001 |

Data are expressed as mean ± SD or median (IQR). *TGF-β1 was measured in only patients with bronchial asthma. ECP: eosinophil cationic protein; ECP/Eo ratio: ECP/eosinophil count ratio; tIgE: total immunoglobulin E; and sIgE: specific IgE.
**Table 5: NGAL and proinflammatory cytokines in allergic patients according to the ECP level and ECP/Eo ratio.**

| Parameters              | ECP test | ECP/Eo ratio |
|-------------------------|----------|--------------|
|                         | Positive (n = 110) | Negative (n = 26) | Elevated (n = 68) | Nonelevated (n = 68) |
| **Lipocalin**           |          |              |                    |                      |
| NGAL (ng/mL)            | 140.5 (71.2–183.0) | 128.0 (61.5–164.5) | 143.5 (80.2–193.7) | 131.0 (60.5–171.8) |
| **Proinflammatory cytokines** |          |              |                    |                      |
| IL-5 (pg/mL)            | 15.8 (10.4–29.5)* | 7.3 (5.1–20.6) | 16.4 (9.8–30.7)* | 8.7 (4.9–21.4) |
| TNF-α (pg/mL)           | 52.7 (8.5–281.2) | 46.2 (7.6–252.9) | 54.1 (9.3–273.1) | 48.5 (6.2–265.3) |
| TGF-β1 (ng/mL)          | 2.76 (1.59–4.61) | 2.43 (1.47–3.84) | 2.83 (1.52–4.86) | 2.47 (1.45–3.96) |
| **Allergic parameters** |          |              |                    |                      |
| tIgE (IU/mL)            | 4.82.6 (41.3–981.5)* | 210.7 (18.3–612.4) |              |                      |
| sIgE score              | 4 (2–5)* | 2 (1–3) | 4 (2–5)* | 2 (1–3) |

Data are expressed as median (IQR). *Significant (P < 0.001), compared with the corresponding group. NGAL: neutrophil gelatinase-associated lipocalin; IL-5: interleukin-5; TNF-α: tumor necrosis factor-α; TGF-β1: transforming growth factor-β1; tIgE: total immunoglobulin E; sIgE: specific IgE; ECP: eosinophil cationic protein; and ECP/Eo ratio: ECP/eosinophil count ratio.

**Table 6: NGAL, ECP, and proinflammatory cytokines according to sIgE and hsCRP levels.**

| Parameters              | sIgE score |                         | Positve ECP test | Nonelevated hsCRP (n = 41) |
|-------------------------|------------|--------------------------|------------------|----------------------------|
|                         | High (n = 86) | Low (n = 50) | Elevated hsCRP (n = 69) |                      |
| **Lipocalin**           |            |              |                   |                      |
| NGAL (ng/mL)            | 152.0 (75.3–194.0) | 128.0 (62.5–171.5) | 181.5 (127.0–236.5)* | 90.2 (60.5–143.0) |
| **Allergic parameters** |            |              |                   |                      |
| ECP (µg/L)              | 62.5 (28.7–95.3)* | 31.4 (25.6–58.1) | 50.1 (30.6–82.3) | 43.2 (29.3–72.8) |
| ECP/Eo ratio            | 0.35 (0.15–9.24)* | 0.14 (0.04–5.61) | 0.28 (0.13–7.06) | 0.23 (0.07–6.84) |
| **Proinflammatory cytokines** |            |              |                   |                      |
| IL-5 (pg/mL)            | 14.3 (7.2–24.6) | 12.7 (6.9–23.5) | 14.5 (7.0–25.8) | 12.9 (6.5–24.1) |
| TNF-α (pg/mL)           | 55.2 (7.1–263.8) | 42.9 (6.5–243.2) | 62.8 (10.4–312.6)* | 30.6 (6.4–231.2) |
| TGF-β1 (ng/mL)          | 2.87 (1.59–4.83) | 2.51 (1.49–3.65) | 3.49 (1.92–5.08)* | 1.81 (1.24–3.25) |

Data are expressed as median (IQR). *Significant (P < 0.001), compared with the corresponding group. NGAL: neutrophil gelatinase-associated lipocalin; ECP: eosinophil cationic protein; ECP/Eo ratio: ECP/eosinophil count ratio; IL-5: interleukin-5; TNF-α: tumor necrosis factor-α; TGF-β1: transforming growth factor-β1; tIgE: total immunoglobulin E; sIgE: specific IgE; ECP: eosinophil cationic protein; and ECP/Eo ratio: ECP/eosinophil count ratio.

**Table 7: Relationship between NGAL, ECP, cytokines, and allergy-related parameters.**

| Parameters              | Multivariate regression analysis* (n = 136) |
|-------------------------|------------------------------------------|
|                         | NGAL | ECP |
| IL-5                    | 0.121 (0.204) | 0.264 (<0.001) |
| TNF-α                   | 0.332 (<0.001) | 0.145 (0.124) |
| TGF-β1                  | 0.285 (<0.001) | 0.157 (0.116) |
| ECP                     | 0.114 (0.213) | NA |
| ECP/Eo ratio            | 0.136 (0.152) | NA |
| hsCRP                   | 0.413 (<0.001) | 0.136 (0.129) |
| tIgE                    | 0.092 (0.307) | 0.327 (<0.001) |
| sIgE                    | 0.105 (0.221) | 0.289 (<0.001) |

Data are expressed as standardized β (P value). *Adjusted for age, sex, BMI, SBP, and current smoking. IL-5: interleukin-5; TNF-α: tumor necrosis factor-α; TGF-β1: transforming growth factor-β1; ECP: eosinophil cationic protein; ECP/Eo ratio: ECP/eosinophil count ratio; hsCRP: high-sensitivity C-reactive protein; tIgE: total immunoglobulin E; sIgE: specific IgE; NGAL: neutrophil gelatinase-associated lipocalin; and NA: not applicable.

In our study, NGAL production in allergic diseases was evaluated in relation to ECP levels and the ECP/Eo ratio. NGAL levels did not differ between the groups categorized by the ECP level and ECP/Eo ratio. However, the plasma NGAL level was two-fold higher in patients with a positive ECP test and hsCRP elevation than in those with a positive ECP test without hsCRP elevation. These results imply that NGAL may not be elevated in the early phase of allergies, in which ECP is released regionally from activated eosinophils, but systemic inflammation is still not evident. However, NGAL appears to rise as allergies progress, particularly when allergies are accompanied by systemic inflammation. Therefore, it is believed that NGAL elevation in allergies may be suggestive of the advanced or complicated state associated with neutrophilic inflammation.

Activated neutrophils release NGAL and matrix metalloproteinase 9 (MMP-9). NGAL binds to MMP-9 and prevents its inactivation, which leads to the increased degradation of matrix proteins and extended effects on collagen breakdown [26, 27]. Several studies reported that NGAL and MMP-9 levels were increased in the
bronchoalveolar lavage samples of patients with asthma as a result of structural alterations in the airways [28, 29]. TGF-$\beta$1 is a profibrotic cytokine associated with airway fibrosis, playing an essential role in most of the cellular biological processes leading to airway remodeling [30]. In our study, TGF-$\beta$1 was measured in patients with bronchial asthma to assess any possible relationship between NGAL and the structural alteration of the airway system. Patients with elevated NGAL exhibited higher TGF-$\beta$1 levels than those without elevated NGAL, and NGAL was positively correlated with TGF-$\beta$1 even after adjustment for confounders. Multivariate logistic regression analysis also revealed that an elevated NGAL level was closely associated with the prevalence of high TGF-$\beta$1. These results are in agreement with

Figure 2: Scatter plots showing the relationship between NGAL and TGF-$\beta$1 in patients with bronchial asthma (a) and between ECP and IL-5 in allergic patients (b).
those of previous studies, showing that TGF-β1 expression was upregulated in bronchial asthma [31], and NGAL levels were higher in asthmatic patients with an obstructive ventilatory defect than in those without an obstructive ventilatory defect [32]. These findings indicate that NGAL elevation in patients with asthma may reflect an evolution of allergic inflammation into the airway structural alteration, mediated by fibrotic transformation.

IL-5 is a cytokine that stimulates the production of eosinophils in the bone marrow and is mostly secreted from lymphocytes, tumor cells, and eosinophils [33, 34]. IL-5 elevation can induce eosinophilia in circulating blood or tissues by triggering eosinophil production and preventing eosinophil destruction [35]. In our study, the IL-5 level was significantly higher in patients with a positive ECP test than in those with a negative ECP test, demonstrating a positive correlation with ECP. However, in patients with a positive ECP test, there was no significant difference in the IL-5 level between those with and without elevated hsCRP. Based on these results, it is estimated that although IL-5 may be closely associated with ECP production, its elevated level may not play a crucial role in the development of systemic inflammation in allergic diseases.

This study has several limitations. Arterial blood gas analysis was not performed to evaluate the status of hypoxemia, which might affect plasma NGAL level. Tissue biopsy and pulmonary function tests were not performed to examine the pathologic findings of airway fibrosis and obstructive ventilatory defect in asthmatic patients. Our patient group consisted of heterogeneous populations with small sample sizes, and the levels of NGAL, ECP, and cytokines could not be assessed according to the types of allergies. As our investigation was a cross-sectional study, the evidence for a cause-and-effect relationship between NGAL and ECP was limited. Hence, further investigation is required to verify our findings in a larger randomized prospective trial.

5. Conclusions

In conclusion, this study demonstrates that augmented NGAL production may be more closely linked to allergic inflammation in conjunction with proinflammatory cytokines than to the intensity of eosinophil activation and the magnitude of atopic sensitization in allergic diseases. High TGF-β1 levels were observed in asthmatic patients with elevated NGAL, suggesting that NGAL elevation may be associated with a potential fibrotic change in the airways in bronchial asthma.

Data Availability

The data used to support the findings of this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by a research grant from Inha University.

References

[1] D. E. Campbell, R. J. Boyle, C. A. Thornton, and S. L. Prescott, "Mechanisms of allergic disease - environmental and genetic determinants for the development of allergy," Clinical and Experimental Allergy, vol. 45, no. 5, pp. 844–858, 2015.
[2] S. J. Galli, M. Tsai, and A. M. Piliponsky, "The development of allergic inflammation," Nature, vol. 454, no. 7203, pp. 445–454, 2008.
[3] K. Bidad, M. H. Nicknam, and R. Farid, "A review of allergy and allergen specific immunotherapy," Iranian Journal of Allergy, Asthma, and Immunology, vol. 10, no. 1, pp. 1–9, 2011.
[4] M. S. Peters, M. Rodriguez, and G. J. Gleich, "Localization of human eosinophil granule major basic protein, eosinophil cationic protein and eosinophil derived neurotoxin by immunoelectron microscopy," Laboratory Investigation, vol. 54, no. 6, pp. 656–662, 1986.
[5] J. D. Young, C. G. Peterson, P. Venge, and Z. A. Cohn, "Mechanism of membrane damage mediated by human eosinophil cationic protein," Nature, vol. 321, no. 6070, pp. 613–616, 1986.
[6] V. Peona, M. De Amici, S. Quaglini et al., "Serum eosinophil cationic protein: is there a role in respiratory disorders?," Journal of Asthma, vol. 47, no. 2, pp. 131–134, 2010.
[7] S. Chakraborty, S. Kaur, S. Guha, and S. K. Batra, "The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer," Biochimica et Biophysica Acta, vol. 1826, no. 1, pp. 129–169, 2012.
[8] A. M. Dittrich, H. A. Meyer, and E. Hamelmann, “The role of lipocalins in airway disease,” *Clinical and Experimental Allergy*, vol. 43, no. 5, pp. 503–511, 2013.

[9] Y. Wang, M. Jia, X. Yan et al., “Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodelling in chronic obstructive pulmonary disease,” *Clinical Science*, vol. 131, no. 11, pp. 1147–1159, 2017.

[10] Y. S. Jo, S. O. Kwon, J. Kim, and W. J. Kim, “Neutrophil gelatinase-associated lipocalin as a complementary biomarker for the asthma-chronic obstructive pulmonary disease overlap,” *Journal of Thoracic Disease*, vol. 10, no. 8, pp. 5047–5056, 2018.

[11] T. M. Eagan, J. K. Damås, T. Ueland et al., “Neutrophil gelatinase-associated lipocalin: a biomarker in COPD,” *Chest*, vol. 138, no. 4, pp. 888–895, 2010.

[12] A. Z. Akelma, M. K. Kanburoglu, M. N. Cizmeci, E. Mete, F. Catal, and N. Tufan, “Level of serum neutrophil gelatinase-associated lipocalin in childhood asthma,” *Allergologia et Immunopathologia*, vol. 43, no. 2, pp. 142–146, 2015.

[13] S. S. Soni, D. Cruz, I. Bobek et al., “NGAL: a biomarker of acute kidney injury and other systemic conditions,” *International Urology and Nephrology*, vol. 42, no. 1, pp. 141–150, 2010.

[14] R. G. Fassett, S. K. Venuthurupalli, G. C. Gobe, J. S. Coombes, M. A. Cooper, and W. E. Hoy, “Biomarkers in chronic kidney disease: a review,” *Kidney International*, vol. 80, no. 8, pp. 806–821, 2011.

[15] J. W. Choi, T. Fujii, and N. Fujii, “Corrected neutrophil gelatinase-associated lipocalin (NGAL) level adjusted by the scoring system of an inflammation index for screening renal dysfunction in patients with systemic inflammation,” *Annals of Clinical and Laboratory Science*, vol. 45, no. 3, pp. 248–255, 2015.

[16] M. H. Lee, J. W. Choi, W. R. Jang, J. M. Kim, and J. H. Kim, “Activation of eosinophils is more closely linked with interleukin-5 and nitric oxide production than tumour necrosis factor-α and immunoglobulin E levels,” *Acta Haematologica*, vol. 130, no. 4, pp. 238–241, 2013.

[17] G. de Vos, R. Nazari, D. Ferastaouer et al., “Discordance between Aeroallergen specific serum IgE and skin testing in children younger than 4 years,” *Annals of Allergy, Asthma, and Immunology*, vol. 110, no. 6, pp. 438–443, 2013.

[18] S. D. Akça, B. Kurt, F. Üçar, E. Erdemir, and E. Alay, “Human neutrophil gelatinase-associated lipocalin: a new biomarker in asthma-COPD overlap syndrome,” *European Respiratory Journal*, vol. 48, article PA5014, suppl 60, 2016.

[19] M. Naqvi, S. Choudhry, H. J. Tsai et al., “Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma,” *Journal of Allergy and Clinical Immunology*, vol. 120, no. 1, pp. 137–143, 2007.

[20] R. A. Wood, W. Phipatanakul, R. G. Hamilton, and P. A. Eggleston, “A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy,” *Journal of Allergy and Clinical Immunology*, vol. 103, no. 5, pp. 773–779, 1999.

[21] J. Bystrom, K. Amin, and D. Bishop-Bailey, “Analyzing the eosinophil cationic protein—a clue to the function of the eosinophil granulocyte,” *Respiratory Research*, vol. 12, no. 1, p. 10, 2011.

[22] A. Trautmann, P. Schmid-Grendelmeier, K. Krüger et al., “T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma,” *Journal of Allergy and Clinical Immunology*, vol. 109, no. 2, pp. 329–337, 2002.

[23] K. Solarewicz-Madejek, T. M. Basinski, R. Crameri et al., “T cells and eosinophils in bronchial smooth muscle cell death in asthma,” *Clinical and Experimental Allergy*, vol. 39, no. 6, pp. 845–855, 2009.

[24] C. Imai, H. Yamazaki, Y. Tanaka, M. Matsunaga, O. Numata, and K. Torigoe, “Ratio of eosinophil cationic protein/eosinophil count as a new marker in children with acute asthma,” *Pediatrics International*, vol. 41, no. 2, pp. 142–146, 1999.

[25] M. Fujitaka, H. Kagawuchi, Y. Kato, N. Sakura, K. Ueda, and Y. Abe, “Significance of the eosinophil cationic protein/eosinophil count ratio in asthmatic patients: its relationship to disease severity,” *Annals of Allergy, Asthma, and Immunology*, vol. 86, no. 3, pp. 323–329, 2001.

[26] K. Gupta, M. Shukla, J. B. Cowland, C. J. Malemud, and T. M. Haqqi, “Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9,” *Arthritis and Rheumatology*, vol. 56, no. 10, pp. 3326–3335, 2007.

[27] L. Yan, N. Borregaard, L. Kjeldsen, and M. A. Moses, “The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL),” *Journal of Biological Chemistry*, vol. 276, no. 40, pp. 37258–37265, 2001.

[28] M. Cundall, Y. Sun, C. Miranda, J. B. Trudeau, S. Barnes, and S. E. Wenzel, “Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids,” *Journal of Allergy and Clinical Immunology*, vol. 112, no. 6, pp. 1064–1071, 2003.

[29] T. Klein and R. Bischoff, “Physiology and pathophysiology of matrix metalloproteases,” *Amino Acids*, vol. 41, no. 2, pp. 271–290, 2011.

[30] Y. C. Yang, N. Zhang, K. Van Crombruggen, G. H. Hu, S. L. Hong, and C. Bachert, “Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling,” *Allergy*, vol. 67, no. 10, pp. 1193–1202, 2012.

[31] S. D. Brown, K. M. Baxter, S. T. Stephenson, A. M. Esper, L. A. Brown, and A. M. Fitzpatrick, “Airway TGF-β1 and oxidant stress in children with severe asthma: association with airflow limitation,” *Journal of Allergy and Clinical Immunology*, vol. 129, no. 2, pp. 388–396.e8, 2012.

[32] J. Kawagoe, Y. Kono, Y. Togashi et al., “Serum neutrophil gelatinase-associated lipocalin (NGAL) is elevated in patients with asthma and airway obstruction,” *Current Medical Science*, vol. 41, no. 2, pp. 323–328, 2021.

[33] W. F. Owen, M. E. Rothenberg, J. Petersen et al., “Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome,” *Journal of Experimental Medicine*, vol. 170, no. 1, pp. 343–348, 1989.

[34] M. Samoszuk and L. Nansen, “Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin’s disease with eosinophilia,” *Blood*, vol. 75, no. 1, pp. 13–16, 1990.

[35] G. M. Walsh, A. Hartnell, A. J. Wardlaw, K. Kurihara, C. J. Sanderson, and A. B. Kay, “IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner,” *Immunology*, vol. 71, no. 2, pp. 258–265, 1990.